AU2008316703B2 - Anti-RSV G protein antibodies - Google Patents

Anti-RSV G protein antibodies Download PDF

Info

Publication number
AU2008316703B2
AU2008316703B2 AU2008316703A AU2008316703A AU2008316703B2 AU 2008316703 B2 AU2008316703 B2 AU 2008316703B2 AU 2008316703 A AU2008316703 A AU 2008316703A AU 2008316703 A AU2008316703 A AU 2008316703A AU 2008316703 B2 AU2008316703 B2 AU 2008316703B2
Authority
AU
Australia
Prior art keywords
seq
positions
region consisting
rsv
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008316703A
Other languages
English (en)
Other versions
AU2008316703A2 (en
AU2008316703A1 (en
Inventor
Ellen J. Collarini
Orit Foord
Lawrence M. Kauvar
Bruce Keyt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of AU2008316703A1 publication Critical patent/AU2008316703A1/en
Publication of AU2008316703A2 publication Critical patent/AU2008316703A2/en
Application granted granted Critical
Publication of AU2008316703B2 publication Critical patent/AU2008316703B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AU2008316703A 2007-10-25 2008-10-24 Anti-RSV G protein antibodies Active AU2008316703B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US61/000,469 2007-10-25
US8940108P 2008-08-15 2008-08-15
US61/089,401 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (3)

Publication Number Publication Date
AU2008316703A1 AU2008316703A1 (en) 2009-04-30
AU2008316703A2 AU2008316703A2 (en) 2010-07-22
AU2008316703B2 true AU2008316703B2 (en) 2012-09-27

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008316703A Active AU2008316703B2 (en) 2007-10-25 2008-10-24 Anti-RSV G protein antibodies

Country Status (14)

Country Link
US (3) US7736648B2 (https=)
EP (1) EP2214711B1 (https=)
JP (2) JP5808536B2 (https=)
KR (1) KR101671452B1 (https=)
CN (1) CN101808663B (https=)
AU (1) AU2008316703B2 (https=)
BR (1) BRPI0819210A2 (https=)
CA (1) CA2703667C (https=)
IL (1) IL205257A (https=)
MX (1) MX2010004482A (https=)
NZ (1) NZ585589A (https=)
RU (1) RU2526517C2 (https=)
WO (1) WO2009055711A2 (https=)
ZA (1) ZA201003131B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874547B2 (ja) * 2002-11-26 2012-02-15 ギリアード サイエンシーズ， インコーポレイテッド 勾配によるリポソームへの薬物充填方法
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
ES2668104T3 (es) * 2011-12-28 2018-05-16 Immunoqure Ag Procedimiento de aislamiento de anticuerpos humanos
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014170257A1 (en) * 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g protein
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
SG11201906682YA (en) 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
WO2021046390A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
EP4031171A1 (en) * 2019-09-20 2022-07-27 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
EP4429966A4 (en) 2021-11-08 2026-01-14 Silgan White Cap LLC PROJECTION ON THE NECK OF A CONTAINER
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
EP1638603A1 (en) 1999-01-22 2006-03-29 The Government of the United States represented by the Secretary of the Department of Health and Human Services Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
DE60136381D1 (de) * 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) * 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2008008858A2 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspot™ applications
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Also Published As

Publication number Publication date
US20100285022A1 (en) 2010-11-11
AU2008316703A2 (en) 2010-07-22
JP2011500091A (ja) 2011-01-06
US9321830B2 (en) 2016-04-26
CA2703667C (en) 2015-12-29
CN101808663B (zh) 2015-09-30
KR101671452B1 (ko) 2016-11-17
RU2010120879A (ru) 2011-11-27
US20130034564A1 (en) 2013-02-07
EP2214711A4 (en) 2011-12-21
WO2009055711A2 (en) 2009-04-30
ZA201003131B (en) 2011-03-30
CA2703667A1 (en) 2009-04-30
US20090130120A1 (en) 2009-05-21
US8273354B2 (en) 2012-09-25
NZ585589A (en) 2012-07-27
IL205257A0 (en) 2010-12-30
JP5808536B2 (ja) 2015-11-10
AU2008316703A1 (en) 2009-04-30
IL205257A (en) 2014-12-31
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
CN101808663A (zh) 2010-08-18
EP2214711B1 (en) 2018-08-15
US7736648B2 (en) 2010-06-15
BRPI0819210A2 (pt) 2015-06-23
RU2526517C2 (ru) 2014-08-20
JP2015078231A (ja) 2015-04-23
WO2009055711A3 (en) 2009-09-24
MX2010004482A (es) 2010-07-06

Similar Documents

Publication Publication Date Title
AU2008316703B2 (en) Anti-RSV G protein antibodies
US7879329B2 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
JP2009528828A (ja) 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
JP2014237714A (ja) 抗ａ型インフルエンザウイルス中和抗体およびその使用
US9688744B2 (en) High affinity human antibodies to human cytomegalovirus (CMV) GB protein
CN115515976A (zh) 冠状病毒抗体
TW202306980A (zh) 一種呼吸道融合病毒的抗體及其應用
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
CN116514965B (zh) 甲型肝炎病毒抗体及其应用
EP4559931A1 (en) Anti-respiratory syncytial virus neutralizing antibody and use thereof
Wang et al. Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes
CN117088971A (zh) 甲型肝炎病毒抗体及其应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 MAY 2010 AND 1 JULY 2010

FGA Letters patent sealed or granted (standard patent)